Zelicapavir for respiratory syncytial virus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Mar 2026: Trial registered, NCT07482657
  2. 9 Jul 2026: Trial started, NCT07482657

The trials

NCT07482657: A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

State
Under way
Phase
Phase 2
People
150 planned
Started
9 Jul 2026
Primary completion
Dec 2026
Arms
zelicapavir
Results
None posted
  1. 19 Mar 2026: Trial registered
  2. 9 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.